Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00893945 : Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors
PhasePhase 1
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion/ Exclusion Criteria:

Screening to determine eligibility (with the exception of HLA haplotyping) will be
completed within 45 days fo study entry.

1. Disease Characteristics

Histologically confirmed brain cancers, reviewed at MSKCC. Pathologic examination
will be of surgical resection specimens deemed of suitable quality for definitive
diagnosis by the histopathologist.

Primary Brain Tumors:

- Anaplastic astrocytoma

- Glioblastoma multiforme

- Anaplastic oligodendroglioma

- Malignant mixed oligoastrocytoma

Secondary (metastatic) brain tumors - newly diagnosed or recurrent disease

- All histological grade of disease accepted

Surgically accessible tumor for which resection is indicated. Tumors may be from
initial resections or re-resections. Recovery of a minimum of 1x10^7 tumor cells ex
vivo is required.

Patients with primary brain tumors must have been previously treated with
conventional therapy.

2. Prior/Concurrent Therapy

1. Recovered from toxicity of any prior therapy

2. Biologic Therapy

- No concurrent other immunotherapy and no prior immunotherapy with any of
the components of the current regimen (autologous DCs, cancer cells, or
KLH)

3. Chemotherapy:

- No concurrent immunomodulatory or chemotherapy therapy

- Chemotherapy, including temozolomide and local chemotherapies such as
Gliadel Wafers, must be deferred until after last post-vaccine
leukapheresis

4. Endocrine evaluation/therapy:

- steroid dose no greater than 1mg daily dexamethasone (or equivalent)

5. Radiotherapy:

- No concurrent brain radiation

6. Surgery:

- Surgical resection must have been completed independently of this study,
and suitable samples obtained for vaccine production

3. Patient Characteristics

1. Age: 18 and over, able to give written informed consent. May be obtained
through use of legal representation such as a health care proxy

2. Performance status: Karnofsky 60-100%

3. Life expectancy: at least 4-6 months

4. Hematopoietic:

- WBC greater than 3,800

- Absolute lymphocytes greater than 500

- Absolute neutrophil counter great than 1,500/mm^3

- Platelets greater than 100,000/mm^3

- Hb greater than or equal to 10g/dL

5. Hepatic: bilirubin less than 2mg/dL OR SGOT less than 2x ULN

6. Renal: Creatinine no greater than 2mg/dL

7. Cardiovascular:

- No NYHA class III/IV status

- No active angina, uncontrolled clinically significant cardiac arrythmia,
recent (6 months) myocardial infarction

8. Pulmonary: No symptomatic pulmonary disease or pulse oximetry less than 93% on
room air

9. Endocrine: No history of autoimmune thyroid disease

10. Radiographic: baseline contrast-enhanced MRI or CT scan of brain post surgical
resection

11. Coagulation: No unexplained INR >2

12. Other:

- No active infection requiring antibiotics

- No history of HIV, hepatitis B or hepatitis C virus infection, no history
of high risk behavior for such infection (intravenous drug abuse, men
having unprotected sex with men). Laboratory evaluation for HIV, hepatitis
B, hepatitis C to be obtained prior to study entry

- No history of hypersensitivity to vaccine components

- No history of autoimmune or vasculitic disease (including but not limited
to systemic lupus erythematosis, Hashimoto's thyroiditis, rheumatoid
arthritis, systemic necrotizing vasculitides (polyarteritis nodosa group),
hypersensitivity vasculitis, Wegener's granulomatosis), scleroderma,
multiple sclerosis, juvenile-onset insulin-dependent diabetes

- No medical or psychiatric illness or social condition that, in the opinion
of the investigator, would interfere with adherence to study requirements

- No alcohol or drug use or dependence that, in the opinion of the
investigator, would interfere with adherence to study requirements
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT00893945      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740